You are here

  • Home
  • Archive
  • Volume 77, Issue 2
  • Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)

Article metrics

Article menu

Download PDFPDF

XML
Clinical and epidemiological research
Extended report
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)

 

Online download statistics by month:

Online download statistics by month: October 2017 to March 2024

AbstractFullPdf
Oct 201722142228493
Nov 201711581206488
Dec 2017593593354
Jan 201812601315426
Feb 2018922955366
Mar 2018642635241
Apr 201860476046195
May 2018684708158
Jun 2018467473189
Jul 2018442442206
Aug 2018429429195
Sep 2018428428199
Oct 2018487496193
Nov 2018606608200
Dec 2018937937203
Jan 2019400388118
Feb 2019404404106
Mar 2019364357111
Apr 2019366346118
May 2019408398140
Jun 2019340338118
Jul 2019363354116
Aug 2019346325116
Sep 201930629690
Oct 2019435425130
Nov 2019304293101
Dec 2019267260118
Jan 2020363344107
Feb 2020309291116
Mar 2020336330105
Apr 2020306298198
May 2020307296235
Jun 2020297278233
Jul 2020311300159
Aug 2020338299124
Sep 2020333300131
Oct 2020258236132
Nov 2020219202107
Dec 202022421088
Jan 202119918884
Feb 2021254232102
Mar 2021447419181
Apr 2021266244111
May 202127826875
Jun 2021230219103
Jul 202117817077
Aug 202121220190
Sep 202127626994
Oct 202126725593
Nov 202119118079
Dec 202118216961
Jan 202216915767
Feb 202218518380
Mar 202221720768
Apr 202219618561
May 202220519960
Jun 202215214648
Jul 202214613643
Aug 202211911736
Sep 202218217178
Oct 202218818265
Nov 202215113761
Dec 202212612436
Jan 202316815845
Feb 202316816248
Mar 202313111532
Apr 202314512643
May 20231009041
Jun 202311510125
Jul 20231069048
Aug 2023937738
Sep 2023887834
Oct 202313511921
Nov 202315614936
Dec 202331230628
Jan 2024807032
Feb 20241028936
Mar 20241029296
Total32237316479679